With shortstop Nick Madrigal due for a long absence with a fractured shoulder, the Mets could reunite with a fan favorite ...

Bill Sibold, Madrigal Pharmaceuticals CEO , joins 'Fast Money' to talk quarterly results.

New York Mets starter Sean Manaea is expected to begin the season on the injured list because of a right oblique strain.

New York Mets infielder Nick Madrigal dislocated his left shoulder in the first inning of the club's split-squad contest ...

New York Mets infielder Nick Madrigal dislocated his non-throwing shoulder in a spring training game against the Washington ...

Citizens JMP raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $443 from $427 and keeps an Outperform rating on the shares.

Madrigal Pharmaceuticals, Inc.'s Rezdiffra, the first approved drug for MASH, showed strong sales growth, with Q4 net sales ...

Citi raised the firm’s price target on Madrigal Pharmaceuticals (MDGL) to $469 from $378 and keeps a Buy rating on the shares post the Q4 ...

Madrigal's Rezdiffra showed significant liver stiffness reduction in MASH cirrhosis. The company also beat Q4 earnings and ...

Shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) were soaring 15.2% higher as of 11:05 a.m. ET on Wednesday. The big gain ...

But the harsh reality is that very many loss making companies burn through all their cash and go bankrupt. So, the natural question for Madrigal Pharmaceuticals (NASDAQ:MDGL) shareholders is whether ...

The Mets’ bench competition experienced some early upheaval on Sunday, when infielder Nick Madrigal dislocated his left ...